2026–2027 COVID-19 Vaccination of People with Moderate or Severe Immunocompromise

Purpose

To facilitate administration of COVID-19 vaccines to moderately or severely immunocompromised individuals. This resource provides the dosing schedules by age and prior vaccination status for all available COVID-19 vaccines.

Sources

Adapted from sections of the September 23, 2026, update of the CDC COVID-19 Vaccination Guidance for People Who Are Immunocompromised (available at www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html), with additional timing considerations from the Infectious Diseases Society of America (IDSA) September 2026 guidance document: www.idsociety.org/practice-guideline/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/.

Who recommends these dosing schedules?

The schedules are based on recommendations of the 2024 Advisory Committee on Immunization Practices (ACIP) published in MMWR December 12, 2024 (www.cdc.gov/mmwr/volumes/73/wr/mm7349a2.htm). The 2026 IDSA guidelines reference these recommendations for completion of an initial series. IDSA routinely recommends only one current season dose for people who have completed an initial series, leaving additional current season doses to clinical judgment. The 2026 American Academy of Pediatrics (AAP) follows these schedules for children, including two doses, 6 months apart, for immunocompromised children who have completed an initial series (see https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf). AAP, IDSA, and CDC use the same definition of conditions for which the modified schedule is recommended.

The recommended dosing schedules of AAP, CDC, and IDSA differ from current FDA labeling. The CDC source document indicates differences between the current FDA label and these recommended dosing tables.

Available products and use of brand or manufacturer names

Products licensed for use in people with moderate or severe immunocompromise for the 2026-2027 season include: **Comirnaty** (Pfizer-BioNTech), age 5 years and older; **Nuvaxovid** (Sanofi-Novavax), age 12 years and older; **Spikevax** (Moderna), age 6 months and older; **mNexspike** (Moderna), age 12 years and older. Brand names are used in dosing tables, except when the two Moderna mRNA products (Spikevax and mNexspike) are interchangeable. Manufacturer names are used for references to historical doses that may be documented only by the manufacturer name before FDA licensure. CDC continues to refer to all products by the manufacturer names.

Description of moderate and severe immunocompromising conditions and treatment

Moderate and severe immunocompromising conditions and treatments include **but are not limited to**:

- Active treatment for solid tumor and hematologic malignancies
- Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
- Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)

CONTINUED ON THE NEXT PAGE ▶

- Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.

For additional information about the degree of immune suppression associated with different medical conditions and treatments, consult General Best Practices for Immunizations, the CDC Yellow Book, and the IDSA policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.

Self-attestation of immunocompromised status

People can self-attest to their moderately or severely immunocompromised status and receive COVID-19 vaccine doses wherever vaccines are offered. Vaccinators should not deny COVID-19 vaccination due to lack of documentation.

CONTINUED ON THE NEXT PAGE ▶

Tables: 2026–2027 COVID-19 vaccination schedule for people who are moderately or severely immunocompromised

AGES 6 MONTHS THROUGH 4 YEARS

Notes: Spikevax (by Moderna) is the only COVID-19 vaccine approved for children age 6 months through 4 years.

Children age 6 through 4 years previously vaccinated with Pfizer-BioNTech COVID-19 vaccine may receive dose(s) of Spikevax.*

COVID-19 vaccination history before 2026–2027 COVID-19 vaccine**	Number of 2026–2027 COVID-19 vaccine doses indicated	Recommended 2026-2027 COVID-19 vaccine† and interval between doses
Unvaccinated: • Administer an initial 3-dose series with 2026–2027 COVID-19 vaccine • Administer 1 dose of 2026–2027 vaccine 6 months after completing initial series		
Unvaccinated	4	**2026–2027 dose 1** (Spikevax): Day 0 **2026–2027 dose 2** (Spikevax): 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Spikevax): At least 4 weeks after 2026–2027 Dose 2 **2026–2027 dose 4** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 3
Initiated but did not complete the 3-dose initial series before 2026–2027 vaccine: • Complete the 3-dose series with 2026–2027 COVID-19 vaccine • Administer 1 dose of 2026–2027 COVID-19 vaccine 6 months after completing initial series		
1 dose Moderna	3	**2026–2027 dose 1** (Spikevax): 4 weeks after last dose **2026–2027 dose 2** (Spikevax): At least 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 2
2 doses Moderna	2	**2026–2027 dose 1** (Spikevax): At least 4 weeks after last dose **2026–2027 dose 2** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 1
1 dose Pfizer-BioNTech	3	**2026–2027 dose 1** (Spikevax): 3 weeks after last dose **2026–2027 dose 2** (Spikevax): At least 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 2
2 doses Pfizer-BioNTech	2	**2026–2027 dose 1** (Spikevax): At least 8 weeks after last dose **2026–2027 dose 2** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 1
Completed the 3-dose initial series before 2026–2027 COVID-19 vaccine: • Administer 2 doses of 2026–2027 COVID-19 vaccine spaced 6 months apart		
3 or more doses Moderna or 3 or more doses Pfizer-BioNTech	2	**2026–2027 dose 1** (Spikevax): At least 8 weeks after last dose **2026–2027 dose 2** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 1

*Pfizer-BioNTech COVID-19 Vaccine is no longer authorized in the United States for children ages 6 months–4 years. Children in this age group who began vaccination with Pfizer-BioNTech COVID-19 Vaccine and have not completed the recommended number of doses should complete vaccination with Spikevax.

**COVID-19 vaccination history refers to all doses from any manufacturer received before the availability of the 2026–2027 COVID-19 vaccines.

†Dosage for Spikevax (Moderna): 0.25 mL/25 mcg.

CONTINUED ON THE NEXT PAGE ▶

AGES 5 THROUGH 11 YEARS

Notes: Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty) COVID-19 vaccines are approved for use for children 5 through 11 years of age. See footnote** for guidance on children who transition from age 4 years to age 5 years during the initial vaccination series.

COVID-19 vaccination history before 2026–2027 COVID-19 vaccine†	Number of 2026–2027 COVID-19 vaccine doses indicated	Recommended 2026-2027 COVID-19 vaccine‡ and interval between doses
Unvaccinated: • Administer an initial 3-dose series with 2026–2027 COVID-19 vaccine • Administer 1 dose of 2026–2027 vaccine 6 months after completing initial series		
Unvaccinated	4	**2026–2027 dose 1** (Spikevax): Day 0 **2026–2027 dose 2** (Spikevax): 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Spikevax): At least 4 weeks after 2026–2027 Dose 2 **2026–2027 dose 4** (Spikevax): 6 months (minimum interval 2 months) after 2026–2027 Dose 3 **OR** **2026–2027 dose 1** (Comirnaty): Day 0 **2026–2027 dose 2** (Comirnaty): 3 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Comirnaty): At least 4 weeks after 2026–2027 Dose 2 **2026–2027 dose 4** (Spikevax or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 3
Initiated but did not complete the 3-dose initial series before 2026–2027 vaccine: • Complete the 3-dose series with 2026–2027 COVID-19 vaccine • Administer 1 dose of 2026–2027 COVID-19 vaccine 6 months after completing initial series		
1 dose Spikevax	3	**2026–2027 dose 1** (Spikevax): 3 weeks after last dose **2026–2027 dose 2** (Spikevax): At least 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Spikevax or Comirnaty): 6 months (minimum interval 2 months) after 2026-2027 Dose 2
2 doses Spikevax	2	**2026–2027 dose 1** (Spikevax): At least 4 weeks after last dose **2026–2027 dose 2** (Spikevax or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1
1 dose Pfizer-BioNTech	3	**2026–2027 dose 1** (Comirnaty): 4 weeks after last dose **2026–2027 dose 2** (Comirnaty): At least 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Spikevax or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 2
2 doses Pfizer-BioNTech	2	**2026–2027 dose 1** (Comirnaty): At least 4 weeks after last dose **2026–2027 dose 2 (**Spikevax or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1
Completed the 3-dose initial series before 2026–2027 COVID-19 vaccine: • Administer 2 doses of 2026–2027 COVID-19 vaccine spaced 6 months apart		
3 or more doses Spikevax or 3 or more doses Pfizer-BioNTech	2	**2026–2027 dose 1** (Spikevax or Comirnaty): At least 8 weeks after last dose **2026–2027 dose 2** (Spikevax or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1

**Children who transition from age 4 years to age 5 years during the initial vaccination series may complete the 3-dose series using the dosage for children ages 5–11 years for all doses received on or after turning age 5 years.

Spikevax series: 2026–2027 Spikevax, 0.25 mL/25 mcg; there is no dosage change
Pfizer-BioNTech series: 2026–2027 Comirnaty, 0.3 mL/10 mcg

†COVID-19 vaccination history refers to all doses from any manufacturer received before availability of the 2026–2027 COVID-19 vaccines.

‡Dosage for Spikevax (Moderna): 0.25 mL/25 mcg; dosage for Comirnaty: 0.3 mL/10 mcg.

CONTINUED ON THE NEXT PAGE ▶

AGES 12 YEARS AND OLDER

Notes: Moderna (mNexspike), Moderna (Spikevax), Sanofi-Novavax (Nuvaxovid), and Pfizer-BioNTech (Comirnaty) COVID-19 vaccines are approved for individuals 12 years and older.

Moderna (mNexspike) and Moderna (Spikevax) may be used interchangeably in the initial 3-dose series and are referred to collectively as Moderna in this table, except where minimum interval differences are noted.

See footnote** for guidance on children who transition from age 11 years to age 12 years during the initial vaccination series.

COVID-19 vaccination history before 2026–2027 COVID-19 vaccine†	Number of 2026–2027 COVID-19 vaccine doses indicated	Recommended 2026-2027 COVID-19 vaccine‡ and interval between doses
Unvaccinated: • Administer an initial series with 2026–2027 COVID-19 vaccine • Administer 1 dose of 2026–2027 COVID-19 vaccine 6 months after completing initial series		
Unvaccinated	4	**2026–2027 dose 1** (Moderna): Day 0 **2026–2027 dose 2** (Moderna): 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Moderna): At least 4 weeks after 2026–2027 Dose 2 **2026–2027 dose 4** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 3; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 3
	OR	
	3	**2026–2027 dose 1** (Nuvaxovid): Day 0 **2026–2027 dose 2** (Nuvaxovid): 3 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 2; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 2
	OR	
	4	**2026–2027 dose 1** (Comirnaty): Day 0 **2026–2027 dose 2** (Comirnaty): 3 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Comirnaty): At least 4 weeks after 2026–2027 Dose 2 **2026–2027 dose 4** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 3; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 3
Initiated but did not complete the initial series before 2026–2027 vaccine: • Complete the initial series with 2026–2027 vaccine • Administer 1 dose of 2026–2027 vaccine 6 months after completing initial series		
1 dose Moderna	3	**2026–2027 dose 1** (Moderna): 4 weeks after last dose **2026–2027 dose 2** (Moderna): At least 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 2; (Moderna [mNexspike]): 6 months (minimum interval 3 months) after 2026–2027 Dose 2
2 doses Moderna	2	**2026–2027 dose 1** (Moderna): At least 4 weeks after last dose **2026–2027 dose 2** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 1

CONTINUED ON THE NEXT PAGE ▶

COVID-19 vaccination history before 2026–2027 COVID-19 vaccine†	Number of 2026–2027 COVID-19 vaccine doses indicated	Recommended 2026-2027 COVID-19 vaccine‡ and interval between doses
Initiated but did not complete the initial series before 2026–2027 vaccine (continued): Complete the initial series with 2026–2027 vaccine • Administer 1 dose of 2026–2027 vaccine 6 months after completing initial series		
1 dose Pfizer-BioNTech	3	**2026–2027 dose 1** (Comirnaty): 3 weeks after last dose **2026–2027 dose 2** (Comirnaty): At least 4 weeks after 2026–2027 Dose 1 **2026–2027 dose 3 (**Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 2; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 2
2 doses Pfizer-BioN-Tech	2	**2026–2027 dose 1** (Comirnaty): At least 4 weeks after last dose **2026–2027 dose 2** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 1
1 dose Nuvaxovid	2	**2026–2027 dose 1** (Nuvaxovid): At least 3 weeks after last dose **2026–2027 dose 2** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 1
Completed the initial series before 2026–2027 vaccine: • Administer 2 doses of 2026–2027 COVID-19 vaccine spaced 6 months apart		
3 or more doses Moderna or 3 or more doses Pfizer-BioNTech	2	**2026–2027 dose 1** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): At least 8 weeks after last dose; (Moderna [mNexspike]): At least 3 months after last dose§ **2026–2027 dose 2** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 1
2 or more doses Nuvaxovid	2	**2026–2027 dose 1** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): At least 8 weeks after last dose; (Moderna [mNexspike]): At least 3 months after last dose§ **2026–2027 dose 2** (Moderna [Spikevax], Nuvaxovid, or Comirnaty): 6 months (minimum interval 2 months) after 2026–2027 Dose 1; (Moderna [mNexspike]): 6 months (minimum interval 3 months)§ after 2026–2027 Dose 1

**Children who transition from age 11 years to age 12 years during the initial vaccination series may complete the 3-dose series using the dosage for people ages 12 years and older for all doses received on or after turning age 12 years.

†COVID-19 vaccination history refers to all doses from any manufacturer received before availability of the 2026–2027 COVID-19 vaccines.

‡Dosage for Moderna (mNexspike): 0.2 mL/10 mcg; dosage for Moderna (Spikevax): 0.5 mL/50 mcg; dosage for Nuvaxovid: 0.5 mL/5 mcg protein and 50 mcg Matrix-M adjuvant; dosage for Comirnaty: 0.3 mL/30 mcg.

§The recommended interval for Moderna (mNexspike) is 3 months after the last dose; however, a dose administered at least 2 months after the last dose should not be repeated.

CONTINUED ON THE NEXT PAGE ▶

Additional Considerations

Development of moderate or severe immunocompromise after vaccination (CDC)

People who were vaccinated for COVID-19 and subsequently become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule for the moderately or severely immunocompromised.

Considerations for revaccination (CDC)

Recipients of HCT or CAR-T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated.

Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in the next section on the timing of vaccination in relation to immunosuppressive therapies.

A patient's clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.

Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies (CDC)

Administration of COVID-19 vaccines should not necessarily be delayed in patients taking immunosuppressive therapies. Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.

Timing of COVID-19 vaccination should take into consideration:

- Current or planned immunosuppressive therapies
- Optimization of both the patient's medical condition and anticipated response to vaccination
- Individual benefits and risks

On a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines through off-label use outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential risks for the recipient who is immunocompromised.

Additional subgroup-specific timing considerations (IDSA)

- Solid Organ Transplant (SOT): Vaccination is optimally timed 2 or more weeks pre-transplant or 3 or more months post-transplant, avoiding periods of pulse immunosuppression and active rejection. Consider earlier administration during high community transmission or based on individual patient risk factors.
- Hematopoietic Cell Transplant (HCT)/CAR-T: Vaccination is recommended 3 or more months post-HCT/CAR-T, or 3 to 6 months (or more) after B-cell depleting therapy, with earlier vaccination considered during high community transmission.
- Hematologic Malignancy: Align vaccination with treatment cycles, ideally 2 or more weeks before new immunosuppression; defer during febrile neutropenia or severe illness. Consider during high community transmission.
- Solid Tumor Chemotherapy: Prefer vaccination 2 or more weeks before therapy, but vaccination during or after therapy is acceptable if needed; defer during severe illness. Consider during high community transmission.
- Primary Immunodeficiency: Vaccinate when clinically stable, aligning with intravenous immunoglobulin (IG) or subcutaneous IG schedules or clinic access; defer during acute illness. Consider during high community transmission.
- Autoimmune Immunosuppression: Vaccinate 2 or more weeks prior to biologics or 3 or more months after therapy; 3 to 6 months or more after B-cell depletion; defer during severe flare or infection. Consider during high community transmission.
- HIV: Vaccinate regardless of CD4 count or viral load, ideally when stable and aligned with preventive routine care; defer during acute illness. Consider during high community transmission.